Phase 1Not yet recruiting
5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses (5FU/C for AKs)
- Sponsor
- Cedars-Sinai Medical Center (Academic or other)
- Enrolment
- 96 planned
- Conditions
- Actinic Keratoses
- Interventions
- Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C)
- Ages
- adults, older adults
- Registry
- NCT07794059
From the registry
Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C) has become standard of care among dermatologists for the field treatment of diffuse actinic keratoses (AKs). Data suggest that the addition of calcipotriene elicits a sustained T cell memory allowing for both short and long-term AK clearance. Our objective is to evaluate the efficacy, as well as, document the timing, severity and duration of local cutaneous reactions to topical treatment with 5FU/C for the treatment of AKs.
Primary outcomes
- To assess the clinical efficacy of 5FU/C to treat Actinic Keratoses